Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
  • Patent number: 10975081
    Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 13, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Yun Jin, Qian Liu, Feng Ren, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Hailong Wang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • Patent number: 10975056
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 13, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.
    Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
  • Patent number: 10961258
    Abstract: Disclosed are compounds having Formula (I): wherein Q, X, A, L, B, Q4, R, RA, R5, n and m are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 30, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventor: Jae U. Jeong
  • Patent number: 10940154
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 9, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Patent number: 10933070
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 2, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Publication number: 20210053955
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g.
    Type: Application
    Filed: February 5, 2019
    Publication date: February 25, 2021
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Anish Bandyopadhyay, Mui Cheung, Hilary Schenck Eidam, Hemant Joshi, Dai-Shi Su
  • Patent number: 10927078
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: February 23, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Martha Alicia De La Rosa, Wieslaw Mieczyslaw Kazmierski, Yoshiaki Washio
  • Publication number: 20210032268
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Application
    Filed: August 15, 2018
    Publication date: February 4, 2021
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Nicolas WILLAND
  • Patent number: 10906924
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: February 2, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Martha Alicia De La Rosa, Hongfeng Deng, Ghotas Evindar, Wieslaw Mieczyslaw Kazmierski, John Franklin Miller, Vicente Samano, Yoshiaki Washio, Bing Xia
  • Patent number: 10899716
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: January 26, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • Patent number: 10899754
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: January 26, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Martha Alicia De La Rosa, Wieslaw Mieczyslaw Kazmierski, Vicente Samano
  • Publication number: 20210009609
    Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 14, 2021
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Patent number: 10870663
    Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: December 22, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Richard M Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
  • Patent number: 10858367
    Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 8, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Feng Ren, Yingxia Sang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • Patent number: 10858631
    Abstract: The invention relates to an adeno-associated virus (AAV) producer cell comprising nucleic acid sequences encoding: rep/cap gene; helper virus genes; and the DNA genome of the AAV vector particle, wherein the nucleic acid sequences are all integrated together at a single locus within the AAV producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that the nucleic acid vectors comprise nucleic acid sequences encoding: rep/cap gene, and helper virus genes. The invention also relates to uses and methods using the nucleic acid vectors in order to produce stable AAV packaging and producer cell lines.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: December 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Conrad Vink
  • Patent number: 10851053
    Abstract: The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 1, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Anthony William Dean, Michael P. DeMartino, Hilary Schenck Eidam, Biswajit Kalita, Raghava Reddy Kethiri, Rajendra Kristam
  • Patent number: 10815218
    Abstract: Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: October 27, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Jessica Fanny Renaux, Robert John Sheppard, Ann Louise Walker, Christopher Roland Wellaway, David Matthew Wilson
  • Publication number: 20200325147
    Abstract: The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: October 24, 2018
    Publication date: October 15, 2020
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David FAVRE, Robert G. FERRIS, Jun TANG
  • Publication number: 20200325126
    Abstract: Disclosed are compounds having the formula: wherein Ra, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 15, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam Kenneth CHARNLEY, Robert Clifford Roback, Robert D. Gilbertson, Hakim Boukhalfa, Scott w. Imbus
  • Patent number: 10799559
    Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 13, 2020
    Assignees: Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell